Anetumab ravtansine
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Anetumab ravtansine
- DrugBank Accession Number
- DB14809
- Background
Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Anetumab ravtansine
- Anti-mesothelin antibody-drug conjugate BAY 94-9343
- External IDs
- BAY 94-9343
- BAY-94-9343
- BAY94-9343
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Anetumab ravtansine. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Anetumab ravtansine. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Anetumab ravtansine. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Anetumab ravtansine. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Anetumab ravtansine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- M170940PMI
- CAS number
- 1375258-01-7
References
- General References
- Not Available
- External Links
- Wikipedia
- ImmunoGen
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Endometrioid Adenocarcinoma of the Fallopian Tubes / High Grade Fallopian Tube Serous Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian High Grade Serous Adenocarcinoma / Platinum drug resistant Fallopian tube cancer / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Primary Peritoneal High Grade Serous Adenocarcinoma 1 2 Completed Treatment Mesothelioma 1 2 Completed Treatment Pancreatic Cancer 1 2 Terminated Treatment Lung Neoplasm 1 2 Terminated Treatment Solid Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:28 / Updated at July 18, 2023 22:57